Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

NCT00092287 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Carcinoid Syndrome

Interventions

DRUG: lanreotide Autogel (somatostatin analogue)
DRUG: Sandostatin long acting release (LAR) Depot (somatostatin analogue)

Sponsor

Ipsen